Pneuma Respiratory, Inc. — SEC Form D Filing

Pneuma Respiratory, Inc. filed an SEC Form D on July 1, 2026, reporting $3.57M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
July 1, 2026
Amount reported
$3.57M
Industry
Medical Devices
Website
https://pneumarespiratory.com/

What the company does

Securities: Equity, Common Stock and Warrants to Purchase Common Stock. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

There is a need for more precise and efficient pulmonary delivery of therapeutics to improve treatment outcomes and reduce systemic exposure.

Solution

Pneuma Respiratory is developing an advanced aerosol generation platform for inhaled therapeutics that enables precise, efficient, and low-shear delivery of both small molecules and fragile biologics to the lungs.

Why now

There is an increasing focus on targeted drug delivery and the development of biologic therapies, which require innovative delivery mechanisms to maintain efficacy and reach specific physiological targets.

Verdict

Investors backed Pneuma Respiratory anticipating that precision pulmonary delivery would unlock new therapeutic potential, especially for biologics. This cleared because the narrative promised a critical enabling technology for a high-value drug class, not because it was addressing an unmet patient need directly. The upside was inherently limited by its reliance on the success and demand for new inhaled biologic drug candidates, making it a picks-and-shovels bet on pharmaceutical R&D rather than a direct market capture play.

Source: SEC EDGAR Form D filing